Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis.
The U.S. Food and Drug Administration greenlit Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) under accelerated approval.
Wrapping up June and ahead of the July 4 holiday, the U.S. Food and Drug Administration has a busy two-week period coming up for drug approval reviews.
The U.S. Food and Drug Administration approved Crysvita (burosumab) for the treatment of a rare disease, tumor-induced osteomalacia.
Shares of Epizyme stock rose after the company’s first-in-class EZH2 inhibitor Tazverik won approval from the U.S. Food and Drug Administration for the second time in 2020.
Roche reported mixed results for a late-stage trial of an experimental drug for prostate cancer, the Swiss drugmaker said on Friday, missing the goal in the overall population but cutting risk of disease worsening in patients with mutated tumors.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
Merck’s vaunted checkpoint inhibitor Keytruda won U.S. approval for a new indication.
GlaxoSmithKline is diving deeper into the realm of synthetic lethality through a new partnership with Bay Area-based IDEAYA Biosciences. The two companies are exploring potential oncology treatments with emerging technology.
In a Phase III study, Eli Lilly’s Verzenio (abemaciclib) combined with standard adjuvant endocrine therapy met the trial’s primary endpoint of invasive disease-free survival in high-risk breast cancer and significantly reduced the risk of a recurrence of the disease.
